Bimekizumab Emerging

“Bimekizumab Market Size, Forecast, and Emerging Insight – 2032” report offers an in-depth analysis of both the market and emerging insights regarding Bimekizumab for the treatment of Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA) in the 7MM. A detailed picture of the Bimekizumab in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the Bimekizumab. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments, including the Bimekizumab market forecast, analysis in the 7MM, descriptive analysis such as SWOT, analyst views, a comprehensive overview of market competitors, and a brief about other emerging therapies.

Drug Summary

BIMZELX (bimekizumab) is the first humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-17A and IL-17F, two key cytokines driving inflammatory processes. IL-17A and IL-17F are the most closely related members of the IL-17 family of cytokines, and they are both co-expressed at sites of inflammation and have overlapping pro-inflammatory functions. Both IL-17A and IL-17F can independently cooperate with other inflammatory mediators to drive chronic inflammation and tissue destruction. UCB is investigating bimekizumab in HS and expects to submit global regulatory applications for bimekizumab in moderate-to-severe HS starting in Q3 2023. 

In March 2023, UCB announced detailed positive results from two Phase III studies (BE HEARD I and BE HEARD II) evaluating the efficacy and safety of bimekizumab in the treatment of adults with moderate-to-severe Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA). Data from the two studies showed that bimekizumab achieved statistically significant and consistent clinically meaningful improvements over the placebo in the signs and symptoms of HS at week 16, which were maintained to week 48. Clinical responses with bimekizumab were observed from the first dose, with some patients achieving HiSCR50 at week four.

Scope of the Report

The report provides insights into:

• A comprehensive product overview includes the description of Bimekizumab, its mechanism of action, dosage and administration, and research and development activities in Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA).
• Elaborated details on Bimekizumab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Bimekizumab research and development activity in Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA) in detail across the United States, Europe and Japan.
• The report also covers the patent's information with an expiry timeline around Bimekizumab.
• The report contains forecasted sales of Bimekizumab for Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA) till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Hidradenitis Suppurativa.
• The report also features the SWOT analysis with analyst views for Bimekizumab in Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA).

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research, and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals, and access to available databases.

Bimekizumab Analytical Perspective by DelveInsight

In-depth Bimekizumab Market Assessment

This report provides a detailed market assessment of Bimekizumab in Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA) in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

Bimekizumab Clinical Assessment

The report provides the clinical trials information of Bimekizumab in Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA) is set to change due to the extensive research and incremental healthcare spending across the world, which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Bimekizumab dominance.
• Other emerging products for Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA) are expected to give tough market competition to Bimekizumab, and the launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones and developmental activities provides the current development scenario of Bimekizumab in Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA).
• Our in-depth analysis of the forecasted sales data from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Bimekizumab in Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA).

Key Questions

• What is the product type, route of administration, and mechanism of action of Bimekizumab?
• What is the clinical trial status of the study related to Bimekizumab in Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA), and the study completion date?
• What are the key collaborations, mergers, acquisitions, licensing, and other activities related to the Bimekizumab development?
• What are the key designations that have been granted to Bimekizumab for Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA)?
• What is the forecasted market scenario of Bimekizumab for Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA)?
• What are the forecasted sales of Bimekizumab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available in Hidradenitis Suppurativa, and how are they giving competition to Bimekizumab for Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA)?
• Which are the late-stage emerging therapies under development for the treatment of Hidradenitis Suppurativa (HS) and Psoriatic Arthritis (PsA)?